Hims & Hers [HIMS] Stock Surges 10.21% to $28.27 After Strong Q4 Revenue Growth

Hims & Hers Health Inc. [NYSE: HIMS] moved back into the market spotlight after the stock climbed 10.21% to $28.27, supported by stronger fourth-quarter revenue growth, steady subscriber gains and renewed buying interest in digital healthcare names.

The move was not just a technical bounce. Investors responded to a stronger operating picture at Hims & Hers, where fourth-quarter revenue rose 59% year over year as demand continued to build across its online healthcare platform. Subscriber growth also improved, rising 13% annually, showing that the company is still adding users despite a more competitive telehealth market.

For traders, the stock’s latest move matters because HIMS is now trading above several important near-term levels. The stock price of $28.27 is above its 20-day simple moving average of $27.19 and well above its 50-day simple moving average of $23.19. That gives short-term bulls a stronger setup, although the longer-term picture remains less clean because HIMS is still below its 200-day moving average of $36.71.

Hims & Hers [HIMS] Stock Key Numbers

• Company: Hims & Hers Health Inc.
• Ticker: HIMS
• Latest stock price: $28.27
• Daily move: +10.21%
• Q4 revenue growth: +59% year over year
• Annual subscriber growth: +13%
• 20-day SMA: $27.19
• 50-day SMA: $23.19
• 200-day SMA: $36.71
• Key support: $25.31 Ichimoku Kijun level
• Near-term trading range: $26.50 to $30.50
• Important resistance: $30.50

Hims & Hers has been trying to convince Wall Street that it is more than a high-growth telehealth story. The company’s business has expanded across sexual health, dermatology, mental health, weight management and other subscription-based care categories. That broader platform is helping the company create recurring revenue streams at a time when investors are paying closer attention to both growth and profitability.

The latest rally also comes as Hims & Hers continues to gain attention for its ability to scale faster than several digital healthcare peers. The company’s revenue momentum has recently been compared favorably with GoodRx Holdings Inc. [NASDAQ: GDRX], strengthening the view that HIMS is becoming a larger player in the consumer healthcare and online pharmacy market.

According to the company’s official financial update, Hims & Hers has continued to report strong growth across its core business. Investors can review the company’s latest results directly through the Hims & Hers investor relations release.

Still, the rally does not remove all risk. Momentum indicators are beginning to show signs that the stock may be stretched in the short term. Daily MACD and ADX signals point to stronger upside momentum, but the weekly MACD remains weaker, suggesting that the broader trend has not fully turned bullish yet.

Other indicators also call for caution. Stochastic RSI, Commodity Channel Index and Bull/Bear Power are showing overbought conditions after the fast move higher. The Awesome Oscillator remains neutral, which means the latest rally has not received full confirmation from every technical signal.

That is why the $30.50 level is important. If HIMS stock breaks above $30.50 with strong volume, traders may see it as confirmation that momentum buyers are back in control. A move above that level could open the door for another leg higher. But if the stock fails near resistance, it may trade sideways while recent gains are absorbed.

The downside level to watch is $26.50. A fall below that area could weaken the current setup and bring the $25.31 support zone back into focus. That level is important because it lines up with the Ichimoku Kijun benchmark, which traders often use as a signal for trend support.

The near-term setup points to a likely consolidation range between $26.50 and $30.00 unless buyers push the stock through resistance. Some analysts see the chance of immediate upside from current levels as limited, with the probability of a strong continuation move below 20% unless new buying pressure appears.

Market expert Anton Kharitonov of Traders Union said Hims & Hers remains supported by strong revenue growth and its move above short- and medium-term averages, but he also warned that momentum may need time to reset. His base case is for consolidation between $26.50 and $30.00, with limited upside unless HIMS clears the $30.50 breakout level.

Swikblog earlier covered related HIMS volatility tied to the company’s weight-loss treatment strategy and investor reaction to GLP-1 developments in this report on HIMS stock and Novo Nordisk developments.

For now, Hims & Hers [HIMS] has given investors a clear reason to pay attention again. A 10.21% rise to $28.27, backed by 59% revenue growth and 13% subscriber growth, shows that the company’s growth story remains active. The question for traders is whether the stock can move beyond a short-term rally and build enough momentum to challenge $30.50. For long-term investors, the bigger focus remains whether Hims & Hers can keep expanding revenue while managing regulatory risk, competition and profitability pressure in the digital healthcare market.

Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.